Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach [Yahoo! Finance]
IN8bio, Inc. (INAB)
Company Research
Source: Yahoo! Finance
Gamma-delta T cells belong to a unique group of immune cells that have qualities of both the innate and adaptive immune systems. They have a complex set of receptors that allow them to differentiate between healthy and cancerous cells. Their multifunctional nature enables them to directly kill cancer cells and activate other immune cells to destroy tumors. What makes gamma-delta T cells particularly promising is that they can eliminate cancer cells without prior exposure to a specific antigen. This means they can trigger a more comprehensive immune response, making them valuable candidates for both solid and hematological cancer therapies. Gamma-delta T cells are also more durable than other innate immune cells like Natural Killer (NK) cells, which have shown to be less effective in clinical trials because of lack of persistence. How IN8bio's Innovative Platform Helps Advance This Promising Research Field IN8bio's innovative DeltEx platform forms the basis of its extensive pipeli
Show less
Read more
Impact Snapshot
Event Time:
INAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INAB alerts
High impacting IN8bio, Inc. news events
Weekly update
A roundup of the hottest topics
INAB
News
- IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]Yahoo! Finance
- IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell EngagerGlobeNewswire
- IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- IN8bio Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire
- IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New SiteGlobeNewswire
INAB
Earnings
- 5/7/25 - Miss
INAB
Sec Filings
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- INAB's page on the SEC website